15/11/2024  8:13:39 Diferencia +0.440 Volumen Bid20:55:35 Ask20:55:35 Capitalización de mecado Dividendo A. P/E Ratio
45.060EUR +0.99% 0
Volumen de negocios: 0.000
-Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 4.77 mil millonesEUR 3.63% 28.96

Descripción de negocio

Orion is a globally operating Finnish developer of pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Consumers with pets are another important customer group. Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organisation covers almost all key European markets. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.
 

Consejo de gestión & Consejo de supervisión

CEO
Liisa Hurme
Consejo de gestión
Jari Karlson, Outi Vaarala, Satu Ahomäki, Virve Laitinen, Juhani Kankaanpää, Olli Huotari
Consejo de supervisión
Mikael Silvennoinen, Ari Lehtoranta, Eija Ronkainen, Hilpi Rautelin, Kari Jussi Aho, Veli-Matti Mattila, Maziar Mike Doustdar, Karen Lykke Sørensen
 

Datos de la empresa

Nombre: Orion Corporation
Dirección: Orionintie 1A,FI-02200 Espoo
Teléfono: +358-10-4261
Fax: -
E-mail: -
Internet: is.gd/3PivOU
Industria: Healthcare
Sector: Healthcare Providers
Subsector: Healthcare Providers
Fin del año financiero: 31/12
Acciones de libre circulación: 97.66%
Fecha de OPI: -

Relación con inversores

Nombre: Jari Karlson
IR teléfono: +358-10-426-2883
IR-fax: -
IR e-mail: -